Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05423652

Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound

Single-center, two-arm, parallel, randomized controlled trial comparing enhanced daily assessments for patients with COPD and/or CHF using point of care ultrasound with PRESUNA software (POCUS-PRESUNA) versus standard care provided by home-based acute care through a tertiary acute care medical teaching hospital. The objectives are to evaluate POCUS-PRESUNA on improving patient experience, provider experience, improve healthcare utilization/costs, and to test the feasibility of incorporating longitudinal POCUS assessments in home-based acute care via remotely acquired images by non-physicians.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

COPD CHF Chronic Disease Disease Attributes Infections Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pneumonia Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rockyview General Hospital

Calgary, Canada

About this study

PRESUNA, a new medical software platform that supports clinicians in optimizing their use of POCUS for CHF and COPD patients in the community, is designed to enhance clinical decision-making and long-term monitoring of patients with CHF and COPD. The aim is to more precisely identify changes in the lungs in order to proactively treat exacerbations and confirm treatment responses. It will also enable practitioners to share information from each scan visually and in a standard format in order to track changes longitudinally. This is expected to reduce potentially avoidable hospitalizations and increase patient quality of life in the community.

This study will implement the use of POCUS enhanced by PRESUNA software in the clinical practice of clinicians on a home hospital (HH) program at a tertiary teaching hospital in Calgary, Alberta. On this home hospital, patients are seen and examined either by home visiting community paramedics who consult with the physician, or in-person by physicians in the home hospital clinic space when expedited diagnostic imaging or investigations are required.

Objective:

To perform a randomized control trial comparing patients with COPD and/or CHF admitted to the HH who will undergo usual care versus usual care enhanced with POCUS and PRESUNA.

Methods:

  • Practitioner Recruitment Home hospital clinicians will be provided information about this study in order to obtain informed consent for participation in the study. Physicians who are already POCUS experts will provide informed consent to undergo training on how to use PRESUNA software and to incorporate POCUS into their home hospital care for intervention study patients. Non-POCUS expert clinicians (community paramedics, some of the physicians and nurses) will provide informed consent to undergo group POCUS training and subsequent individual training sessions in order to enable them to become proficient at using POCUS. They will also consent to being trained on how to use PRESUNA software, as well as incorporating POCUS and PRESUNA into their home hospital care for intervention arm patients.
  • Patient Recruitment Patients admitted to HH with CHF and/or COPD will be approached to participate in the research study by the Nurse Navigator or Research Assistant. Those that provide informed consent will be randomized (1:1) to the intervention (POCUS-PRESUNA enhanced HH care) versus control group (usual HH care).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patient Inclusion Criteria:

  • 18 years of age or older
  • Has a provincial health care number
  • Functionally safe to receive HH care or have sufficient caregiving to support them at home
  • Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day
  • Able and willing to follow a management plan
  • Provides consent to receive care on HH
  • Diagnosis of CHF and/or COPD that requires HH care
  • No painful/broken ribs that could be affected by pressure applied when performing lung POCUS

Patient Exclusion Criteria:

  • Not eligible for HH care
  • New unstable rib fractures
  • Prior history of allergy to ultrasound gel
  • Participant refusal to participate in research study

Provider inclusion criteria

  • Attending clinician on the home hospital program within the next 3-6 months
  • Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA

Provider exclusion criteria

  • Not a home hospital clinician
  • Refuses to consent for the study / training.

Treatment and study plan

Lung point of care ultrasound

Device

Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.

Other names: POCUS

PRESUNA software

Other

PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.

Primary outcomes

  1. Length of stay

    Time frame: From the date of admission to discharge from the index admission, assessed up to 1 year

    Length of stay for index Home Hospital admission

Secondary outcomes

  1. Patient outcome - Time to resolution of infection

    Time frame: Assessed up to 24 months after infection identified

    return to baseline oxygen saturation and normalization of white blood cell count

  2. Patient outcome - time to decongestion

    Time frame: Assessed up to one year after congestion identified

    absence of crackles and baseline oxygen saturation on lung examination

  3. Patient outcome - rate of change in NT-BNP

    Time frame: Change from admission to when decongestion occurred, assessed up to 12 months

    Difference between NT-BNP on admission and at time of decongestion over total number of days

  4. Patient outcome - Admission to facility living

    Time frame: From date and time of discharge from index admission, assessed up to 12 months

    Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission

  5. Patient outcome - Escalation of care

    Time frame: From date of randomization until the patient is discharged from the index admission (assessed up to 12 months).

    Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital.

  6. Patient outcome - Adverse events

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first until the patient is discharged from the hospital (assessed up to 12 months).

    Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium)

  7. Patient outcome - Mortality

    Time frame: From date of randomization until the date of death, assessed up to 12 months

    Date and cause of mortality of occurrence of mortality

  8. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)

  9. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)

  10. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme).

  11. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity

  12. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely).

  13. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome

  14. Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS)

    Time frame: At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge

    Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine)

  15. Patient experience

    Time frame: Upon discharge from the Home Hospital (up to 7 business days post-discharge)

    Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure".

  16. Provider experience

    Time frame: Within 1 week of being on the Hospital at Home service

    Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree"

  17. Healthcare utilization cost - Diagnostic testing

    Time frame: Between the date and time of hospital admission to up to 3 months post-discharge

    Cost of Diagnostic testing

  18. Healthcare utilization - Incidence rate ratio of acute care days pre/during/post

    Time frame: 90 days before randomization until 90 days after index admission (assessed up to 15 months)

    Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission

  19. Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post

    Time frame: 90 days before, during and 90 days after index admission

    Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission

  20. Cost analysis

    Time frame: From date of admission until the date of discharge from the index admission, assessed up to 12 months").

    Incremental effectiveness ratio for the index admission

  21. Cost analysis

    Time frame: From date of discharge from index admission, assessed up to 90 days.

    Incremental effectiveness ratio for healthcare utilization post-discharge

Sponsors and collaborators

Lead sponsor

Michelle Grinman

Other

Collaborators

  • Alberta Boehringer Ingelheim Collaboration
  • Institute of Health Economics, Canada
  • PRESUNA

Registry information

Acronym: ACCUMEN-POCUS

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 21, 2022
Registry last updated
Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.